The RIGHT Fund is approaching its one-year anniversary, and we are proud to share our accomplishments with our existing and potential partners.

The RIGHT (Research Investment for Global Health Technology) Fund is the first public private partnership built between three different funding sectors—the Korean government, Korean industries, and international funders—with the mission of enhancing public health in developing countries.

The RIGHT Fund has been established and will serve as the platform for the Korean government to contribute to developing countries, and for Korean industries to introduce direct and innovative solutions for public health leveraging their own R&D strengths. The technological advancements that will be financed and generated through the RIGHT Fund will not only benefit the target countries, but will also bring about innovations to improve global health.

Since the legal registration of the RIGHT Fund in July 2018, we together with our officers and team members have established our governance & management, business model, and investment priorities & process. In October 2018, we issued our first call for proposals and we are about to announce our first awardees.

This is only the first step. We see that there are many more investment opportunities where the RIGHT Fund can make a large impact, and good partnerships are critical for achieving these goals.

We appreciate all of the support from our existing partners, and we continue to seek new partnerships to help us make progress toward our mission.

CHAIRMAN OF THE BOARD
CHANGJIN MOON

CEO & EXECUTIVE DIRECTOR
YOUNBEEK KIM

A Small First Step to Make a Big Impact

Who we are

Established in 2018 and based in Seoul, the RIGHT Fund is the first public private partnership between the Korean Government, Korean pharma companies, and the Bill and Melinda Gates Foundation.

Seeking practical investments on projects to deliver tangible global health solutions, we invest in original and innovative concepts for vaccines, therapeutics, and diagnostics to alleviate the acquisition, progression, or transmission of infectious diseases emerging and endemic in developing countries through our annual call for proposals.

Vision

To alleviate the burden of infectious diseases that disproportionately affect the people in low-resource countries

Mission

To mobilize Korea’s innovation and leadership to advance global health equity by promoting the discovery and development of new technologies that will meet the public health needs of developing countries.

THE RIGHT FUND 2018/19
**Investment Priorities 2018-2022**

The RIGHT Fund seeks to improve global health through innovative health intervention technologies relating to diagnostics, vaccines, and drugs.

**01** FOCUS ON UNMET MEDICAL NEEDS
- Projects addressing specific unmet needs (e.g., lack of treatment options, patient access, and usage, high cost, etc.)
- Projects that maximize impact on public health (lives saved and DALYS)

**02** LEVERAGE KOREAN INDUSTRIAL STRENGTHS
- Identify projects that best utilize emerging or specific technologies based on the strengths of Korean industry
- Foster collaboration among local and international organizations

**03** BUILD CAPACITY FOR KOREAN RESEARCH AND DEVELOPMENT
- Projects that can enrich the local pipeline for public health indications
- Support the localization of product development and manufacturing

**04** EXTEND THE ENGAGEMENT OF KOREAN INDUSTRY, R&D ORGANIZATIONS, AND INSTITUTIONS WITH GLOBAL HEALTH INITIATIVES

---

**Focused Investment Area**

- **VACCINES**
  - New vaccines for target diseases
  - New pediatric combination vaccines

- **THERAPEUTICS**
  - New chemical or biological approaches for currently unmet needs

- **DIAGNOSTICS**
  - New diagnostics and those that can improve efficiency of treatments
  - Point-of-Care diagnostics
  - Proof of concept for ICT combined diagnostics

**Eligible Development Stages**

- **VACCINES AND THERAPEUTICS**
  - Preclinical
  - Phase I
  - Phase II
  - Phase III
  - Registration

- **DIAGNOSTICS**
  - Product Development
  - Product Validation (Early)
  - Product Validation (Late)
  - Clinical Validation/Utility
  - Registration
To mitigate any conflicts of interests, the RIGHT Fund has adopted a governance structure that ensures a transparent and equitable framework for the selection and advancement of new healthcare innovations, and access to them.

A well-planned and interlocking set of leadership bodies and functions has been designed to achieve this goal. The RIGHT Fund leadership team is organized into four separate but related bodies—the Board of Directors, Council, Selection Committee, and Management Team—that perform independent roles and collectively contribute to achieve the goals of the organization.

To mitigate any conflicts of interests, the RIGHT Fund has adopted a governance structure that ensures a transparent and equitable framework for the selection and advancement of new healthcare innovations, and access to them.

A well-planned and interlocking set of leadership bodies and functions has been designed to achieve this goal. The RIGHT Fund leadership team is organized into four separate but related bodies—the Board of Directors, Council, Selection Committee, and Management Team—that perform independent roles and collectively contribute to achieve the goals of the organization.